» Articles » PMID: 28306519

Variability In, Variability Out: Best Practice Recommendations to Standardize Pre-analytical Variables in the Detection of Circulating and Tissue MicroRNAs

Overview
Specialties Biochemistry
Pathology
Date 2017 Mar 18
PMID 28306519
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

microRNAs (miRNAs) hold promise as biomarkers for a variety of disease processes and for determining cell differentiation. These short RNA species are robust, survive harsh treatment and storage conditions and may be extracted from blood and tissue. Pre-analytical variables are critical confounders in the analysis of miRNAs: we elucidate these and identify best practices for minimizing sample variation in blood and tissue specimens. Pre-analytical variables addressed include patient-intrinsic variation, time and temperature from sample collection to storage or processing, processing methods, contamination by cells and blood components, RNA extraction method, normalization, and storage time/conditions. For circulating miRNAs, hemolysis and blood cell contamination significantly affect profiles; samples should be processed within 2 h of collection; ethylene diamine tetraacetic acid (EDTA) is preferred while heparin should be avoided; samples should be "double spun" or filtered; room temperature or 4 °C storage for up to 24 h is preferred; miRNAs are stable for at least 1 year at -20 °C or -80 °C. For tissue-based analysis, warm ischemic time should be <1 h; cold ischemic time (4 °C) <24 h; common fixative used for all specimens; formalin fix up to 72 h prior to processing; enrich for cells of interest; validate candidate biomarkers with in situ visualization. Most importantly, all specimen types should have standard and common workflows with careful documentation of relevant pre-analytical variables.

Citing Articles

Review of microRNA detection workflows from liquid biopsy for disease diagnostics.

Naranbat D, Herdes E, Tapinos N, Tripathi A Expert Rev Mol Med. 2025; 27:e11.

PMID: 39911053 PMC: 11879380. DOI: 10.1017/erm.2025.2.


Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma.

Wnuk J, Hudy D, Strzelczyk J, Michalecki L, Dybek K, Gisterek-Grocholska I Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852142 PMC: 11763715. DOI: 10.3390/cimb47010027.


Postmortem analyses of myocardial microRNA expression in sepsis.

Lehto P, Skarp S, Saukko T, Sakkinen H, Syrjala H, Kerkela R Sci Rep. 2024; 14(1):29476.

PMID: 39604475 PMC: 11603066. DOI: 10.1038/s41598-024-81114-6.


Preanalytical, analytical and postanalytical considerations in circulating microRNAs measurement.

Zendjabil M Biochem Med (Zagreb). 2024; 34(2):020501.

PMID: 38882585 PMC: 11177657. DOI: 10.11613/BM.2024.020501.


Candidate circulating microRNA biomarkers in dogs with chronic pancreatitis.

Armstrong S, Hunter R, Oosthyuzen W, Parys M, Gow A, Salavati Schmitz S J Vet Intern Med. 2024; 38(2):995-1004.

PMID: 38351718 PMC: 10937508. DOI: 10.1111/jvim.17009.